2025-07-14 - Analysis Report
## RXRX (Recursion Pharmaceuticals Inc) Analysis Report

Here's an analysis of Recursion Pharmaceuticals Inc (RXRX), focusing on its performance relative to the S&P 500 (VOO), recent stock movements, key indicators, news, and financial data.

**Company Overview:** Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to discover, develop, and commercialize novel therapeutics.

**1. Performance vs. S&P 500 (VOO)**

*   **Cumulative Return:**
    *   RXRX: -51.14%
    *   VOO: 34.56%
*   **Divergence:** -85.7 (Last day cumulative return difference)
*   **Relative Divergence:** 1.9 (RXRX's performance is near the bottom of its historical divergence range compared to VOO.)

**Analysis of Alpha, Beta, CAGR, MDD:**

| Year       | CAGR    | MDD     | Alpha   | Beta  | Cap(B) |
|------------|---------|---------|---------|-------|--------|
| 2021-2023  | 5.0%   | 73.6%   | -1.0%   | -0.1 | 4.3    |
| 2022-2024  | 0.0%   | 73.6%   | -25.0%  | 0.1  | 3.0    |
| 2023-2025  | 0.0%   | 73.6%   | -47.0%  | 0.1  | 2.3    |

*   **CAGR:** RXRX's Compound Annual Growth Rate has been volatile over the specified periods, showing growth, but recently stabilizing at 0.0%.
*   **MDD:** The Maximum Drawdown (MDD) remains consistently high at 73.6%, indicating significant potential loss from peak to trough.
*   **Alpha:** The Alpha values are negative, indicating that RXRX has underperformed relative to its benchmark.
*   **Beta:** The Beta values are low, suggesting that RXRX's price is not very sensitive to market movements.
*   **Cap(B):** The market capitalization has decreased from $4.3 billion to $2.3 billion.

The significant negative Alpha values suggest that RXRX's returns are not driven by market factors, and the consistently high MDD indicates a high level of risk. The decreasing market capitalization could indicate declining investor confidence.

**2. Recent Stock Price Movement**

*   **Current Price:** $5.28
*   **Last Market Data:**
    *   Price: $5.375
    *   Previous Close: $5.28
    *   Change: 1.8%
*   **Moving Averages:**
    *   5-day: $5.375
    *   20-day: $5.1635
    *   60-day: $4.9836

**Analysis:** The stock price shows an upward trend, with the current price above the 20-day and 60-day moving averages. The recent 1.8% price increase suggests positive momentum.

**3. Key Indicators**

*   **Market Risk Indicator (MRI):** 0.3294 (Low Risk)
*   **RSI:** 54.08
*   **PPO:** 0.5258
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.34)
*   **Recent (20-day) Relative Divergence Change:** 0.8 (+) (Short-term increase)
*   **Expected Return (%):** -1351.7 (Significant underperformance vs. S&P 500 over 2+ year investment horizon)

**Analysis:** The MRI indicates low market risk.  RSI around 54 suggests neutral momentum. The positive change in relative divergence indicates short-term upward momentum. The Hybrid Signal suggests caution with 80% cash allocation. The significantly negative expected return is concerning, suggesting potential underperformance relative to the S&P 500. The 1.8% change reflects recent volatility.

**4. Recent News & Significant Events**

*   **[2025-07-13]:** Major business developments, regulatory changes, or market events impacting RXRX.
*   **[2025-07-12]:** Analysts discussing RXRX's performance within the context of industry and economic trends.
*   **[2025-07-14]:** Notable stock volatility influenced by recent news, earnings, or executive actions.
*   **[2025-07-10]:** Market experts highlighting both risks and opportunities, advising monitoring of news and announcements.

**Analysis:** The recent news suggests that RXRX is experiencing significant events that are causing volatility. Investors should closely monitor news and announcements for further developments.

**5. Recent Earnings Analysis**

| 날짜       | EPS    | 매출      |
|------------|--------|-----------|
| 2025-05-05 | -0.50  | 0.01 B$   |
| 2024-11-06 | -0.34  | 0.03 B$   |
| 2024-08-08 | -0.40  | 0.01 B$   |
| 2024-05-09 | -0.39  | 0.01 B$   |
| 2025-05-05 | -0.39  | 0.01 B$   |

**Analysis:** The company is consistently reporting negative EPS, indicating unprofitability. Revenue has been variable, but generally low. This raises concerns about the company's financial stability.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-03-31 | $0.01B   | -47.31%       |
| 2024-12-31 | $0.00B   | -183.62%      |
| 2024-09-30 | $0.03B   | 53.69%        |
| 2024-06-30 | $0.01B   | 36.14%        |
| 2024-03-31 | $0.01B   | 17.23%        |

**Capital and Profitability:**

| Quarter    | Equity   | ROE      |
|------------|----------|----------|
| 2025-03-31 | $0.93B   | -21.68%  |
| 2024-12-31 | $1.03B   | -17.29%  |
| 2024-09-30 | $0.52B   | -18.27%  |
| 2024-06-30 | $0.58B   | -16.69%  |
| 2024-03-31 | $0.40B   | -22.78%  |

**Analysis:** Revenue has fluctuated, with a mix of positive and negative profit margins. Equity has been increasing, but Return on Equity (ROE) is consistently negative, indicating poor profitability relative to equity.

**7. Overall Summary**

Recursion Pharmaceuticals Inc (RXRX) is experiencing a complex situation. While there is recent positive momentum in the stock price, several factors raise concerns:

*   **Significant Underperformance:** RXRX has significantly underperformed the S&P 500, with a large negative cumulative return divergence.
*   **Financial Instability:**  The company reports consistent negative EPS, fluctuating revenue, and negative ROE.
*   **High Risk:** The high MDD and volatile performance suggest a high-risk investment.
*   **Negative Expected Return:** The significantly negative expected return suggests that RXRX is projected to underperform the S&P 500 substantially over the long term.
*   **Recent Volatility:** Recent news and events are causing significant volatility in the stock price.
*   **Hybrid Signal:**  It Suggests caution is warranted.

**Conclusion:** Investors should exercise caution when considering RXRX. The company faces significant financial challenges and high risk. Close monitoring of news, earnings reports, and company announcements is crucial. The positive short-term price movement and recent deals might offer opportunities, but the overall risk profile remains elevated.
